Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?
Journal
Contrast media & molecular imaging
ISSN: 1555-4317
Titre abrégé: Contrast Media Mol Imaging
Pays: England
ID NLM: 101286760
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
07
2021
revised:
10
10
2021
accepted:
29
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
26
4
2022
Statut:
epublish
Résumé
Cancer-associated fibroblasts (CAFs) can strongly modulate the response to therapy of malignant tumor cells, facilitating their continuous proliferation and invading behaviors. In this context, several efforts were made in identifying the fibroblast activation protein (FAP) as a CAF recognizer and in designing FAP-specific PET radiotracers (as A comprehensive systematic search was conducted on the PubMed and Scopus databases to find relevant published articles concerning the FAP-specific PET imaging as well as the FAP-specific radionuclide therapy in patients with oncologic and nononcologic indications. The enrolled studies were dichotomized into oncologic and nononcologic categories, and the required data were extracted by precisely reviewing the whole text of each eligible study. A meta-analysis was also performed comparing the detection rates of Of the initial 364 relevant papers, 49 eligible articles (1479 patients) and 55 case reports were enrolled in our systematic review. These studies observed high radiolabeled FAPI avidity as early as 10 minutes after administration in primary sites of various malignant tumors. Based on the meta-analysis which was done on the reported detection rates of the The outperformance of
Sections du résumé
Background
Cancer-associated fibroblasts (CAFs) can strongly modulate the response to therapy of malignant tumor cells, facilitating their continuous proliferation and invading behaviors. In this context, several efforts were made in identifying the fibroblast activation protein (FAP) as a CAF recognizer and in designing FAP-specific PET radiotracers (as
Methods
A comprehensive systematic search was conducted on the PubMed and Scopus databases to find relevant published articles concerning the FAP-specific PET imaging as well as the FAP-specific radionuclide therapy in patients with oncologic and nononcologic indications. The enrolled studies were dichotomized into oncologic and nononcologic categories, and the required data were extracted by precisely reviewing the whole text of each eligible study. A meta-analysis was also performed comparing the detection rates of
Results
Of the initial 364 relevant papers, 49 eligible articles (1479 patients) and 55 case reports were enrolled in our systematic review. These studies observed high radiolabeled FAPI avidity as early as 10 minutes after administration in primary sites of various malignant tumors. Based on the meta-analysis which was done on the reported detection rates of the
Conclusions
The outperformance of
Identifiants
pubmed: 35280710
doi: 10.1155/2022/3948873
pmc: PMC8888077
doi:
Substances chimiques
Gallium Radioisotopes
0
Ligands
0
Membrane Proteins
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Endopeptidases
EC 3.4.-
fibroblast activation protein alpha
EC 3.4.21.-
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3948873Informations de copyright
Copyright © 2022 Hessamoddin Roustaei et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this article.
Références
Ann Rheum Dis. 2020 Nov;79(11):1485-1491
pubmed: 32719042
Radiother Oncol. 2021 May;158:55-61
pubmed: 33621587
Radiother Oncol. 2020 Sep;150:159-163
pubmed: 32598977
EJNMMI Res. 2021 Feb 19;11(1):18
pubmed: 33606104
Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3493-3501
pubmed: 33829416
Radiology. 2021 Feb;298(2):393-402
pubmed: 33258746
J Nucl Med. 2022 Mar;63(3):415-423
pubmed: 34168013
J Nucl Med. 2020 Aug;61(8):1171-1177
pubmed: 31836685
J Nucl Med. 2020 Sep;61(9):1331-1336
pubmed: 32060216
Clin Nucl Med. 2021 Sep 1;46(9):774-775
pubmed: 33883497
Clin Nucl Med. 2021 Aug 1;46(8):641-646
pubmed: 33883494
BMC Med Res Methodol. 2006 Jul 12;6:31
pubmed: 16836745
Ann Nucl Med. 2021 Jun;35(6):744-752
pubmed: 33934311
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2635-2641
pubmed: 33452634
Clin Nucl Med. 2020 Nov;45(11):865-867
pubmed: 32969904
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832
pubmed: 32222810
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1178-1187
pubmed: 33057927
J Nucl Cardiol. 2021 Jun;28(3):812-821
pubmed: 32975729
Cancers (Basel). 2021 Mar 04;13(5):
pubmed: 33806468
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1593-1603
pubmed: 33097975
Front Cell Dev Biol. 2019 Apr 24;7:60
pubmed: 31106200
Endocrine. 2021 Aug;73(2):485-486
pubmed: 33449295
Clin Nucl Med. 2021 Jul 1;46(7):601-602
pubmed: 33782317
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3228-3237
pubmed: 33609152
Cancers (Basel). 2021 Feb 14;13(4):
pubmed: 33672893
Clin Nucl Med. 2021 Jun 1;46(6):520-522
pubmed: 33661208
Circ Cardiovasc Imaging. 2020 Sep;13(9):e010628
pubmed: 32912030
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4377-4385
pubmed: 34137945
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2059-2061
pubmed: 33543324
J Nucl Med. 2021 Feb;62(2):201-207
pubmed: 32591493
J Nucl Med. 2022 Jan;63(1):81-88
pubmed: 33863819
Cancers (Basel). 2020 Sep 15;12(9):
pubmed: 32942573
Front Oncol. 2021 Mar 11;11:651005
pubmed: 33777814
Physiol Rev. 2021 Jan 1;101(1):147-176
pubmed: 32466724
Clin Nucl Med. 2021 Nov 1;46(11):e534-e537
pubmed: 33826564
Clin Nucl Med. 2021 May 1;46(5):e293-e295
pubmed: 33351506
J Nucl Med. 2021 Jun 1;62(6):779-786
pubmed: 33097632
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4089-4100
pubmed: 34050777
Clin Nucl Med. 2020 Oct;45(10):e430-e432
pubmed: 32332301
J Nucl Med. 2021 Feb;62(2):266-271
pubmed: 32513902
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4396-4414
pubmed: 34173007
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):73-86
pubmed: 32588089
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1604-1617
pubmed: 33179149
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3221-3227
pubmed: 33620560
Clin Nucl Med. 2021 Feb 1;46(2):e86-e87
pubmed: 32701818
Clin Nucl Med. 2021 Aug 1;46(8):e433-e435
pubmed: 33782295
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):196-203
pubmed: 32468254
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):924-926
pubmed: 32651662
Mol Imaging Biol. 2020 Dec;22(6):1495-1500
pubmed: 33063132
Clin Nucl Med. 2020 Dec;45(12):1034-1035
pubmed: 33086278
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3951-3960
pubmed: 34050405
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1254-1255
pubmed: 32901354
Clin Nucl Med. 2021 Aug 1;46(8):683-685
pubmed: 33826569
Clin Nucl Med. 2021 Feb 1;46(2):175-176
pubmed: 33208623
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Clin Nucl Med. 2021 Aug 1;46(8):694-696
pubmed: 33826568
Clin Nucl Med. 2020 Apr;45(4):310-311
pubmed: 31977474
Clin Nucl Med. 2021 Aug 1;46(8):700-702
pubmed: 33826575
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1915-1931
pubmed: 33244617
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2836-2845
pubmed: 32447444
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3918-3924
pubmed: 34018010
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):651-652
pubmed: 32643006
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1944-1955
pubmed: 33415432
Radiother Oncol. 2021 Jul;160:192-201
pubmed: 33940087
Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3606-3617
pubmed: 33792760
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Front Cardiovasc Med. 2021 Feb 25;8:614997
pubmed: 33718446
J Nucl Med. 2020 Oct;61(10):1507-1513
pubmed: 32169911
Semin Cell Dev Biol. 2010 Feb;21(1):33-9
pubmed: 19896548
Int J Surg. 2010;8(5):336-41
pubmed: 20171303